|
Accentia Biopharmaceuticals emphasizes runny noses. The company acquires and develops treatments for respiratory conditions, as well as other ailments. Its development-stage drugs include sinus inflammation treatment SinuNase, multiple sclerosis drug Revimmune, and BiovaxID, a possible vaccine for non-Hodgkin's lymphoma being developed by majority-owned subsidiary Biovest International. Accentia also develops cell production instruments, including the AutovaxID system, and offers pharmaceutical consulting services. The company and its subsidiaries (including Biovest) filed for Chapter 11 bankruptcy protection in late 2008.
|
| | | Contact Information | |
Address: |
324 S. Hyde Park Ave., Ste. 350
Tampa, FL 33606
| | Phone: | 813-864-2554 | | Fax: | 813-258-6912 |
|
| Financial
Highlights | | Fiscal Year End: | September | | Revenue (2007): | 18.30 M | | Revenue Growth (1 yr): | (-27.00%) | | Employees (2007): | 140 | | Employee Growth (1 yr): | (-45.70%) |
|
|
Key People
| | • |
Chairman and CEO:
Francis E. O'Donnell Jr.
| | • |
President, General Counsel, and Director:
Samuel S. (Sam) Duffey
| | • |
CFO and Director:
Alan M. Pearce
|
|
|
